Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering SPC-15, its lead intranasal therapeutic for post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes both composition and method claims related to the company’s proprietary approach to preventing or delaying stress-induced behavioral responses. A corresponding patent was issued by the Japan Patent Office earlier this year.
A Notice of Allowance indicates that the USPTO has completed its examination and determined that the application meets the requirements for patentability and should be granted shortly. This development is significant because it provides Silo Pharma with exclusive rights to SPC-15 in the United States, a key market for pharmaceutical innovation. The patent protection is an important component of the company’s strategy as it advances SPC-15 development for PTSD, adding to its biopharmaceutical intellectual property portfolio of issued and allowed patents. For investors, this milestone reduces competitive risks and enhances the commercial potential of SPC-15, which is designed to address a serious mental health condition with limited treatment options.
PTSD affects millions of people worldwide, and current therapies often have limitations in efficacy and accessibility. SPC-15’s intranasal delivery could offer a more convenient and rapid-acting option, potentially improving patient compliance. The patent allowance not only validates the novelty of Silo’s approach but also strengthens its position in the growing neuropsychiatric drug market. This could attract partnership opportunities or accelerate clinical trials, as intellectual property protection is a prerequisite for attracting investment in biotech.
For a full view of the press release, visit https://ibn.fm/Hh4Z6. The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO. For more information about BioMedWire, please visit https://www.BioMedWire.com.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
